Low-dose oral sildenafil for patients with pulmonary hypertension: A cost-effective solution in countries with limited resources

Cardiology in the Young

Volumn 17, Issue 1, 2007, Pages 72-77

  Vida, Vladimiro L ^a   Gaitan, Guillermo ^a   Quezada, Emilio ^a   Barnoya, Joaquin ^a   Castañeda, Aldo R ^a  

^a Pediatric Cardiac Surgery Unit of Guatemala   (Guatemala)

Author keywords

Open label; Oral medication; Pulmonary vascular disease

Indexed keywords

BOSENTAN; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; UNIPROST;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLOR VISION; CONGENITAL HEART DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FUNCTIONAL STATUS; HEADACHE; HEART CATHETERIZATION; HUMAN; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PRESCHOOL CHILD; PULMONARY HYPERTENSION; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHILD; DRUG COSTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PIPERAZINES; PURINES; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33847263010     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951106001193     Document Type: Article

References (32)

1. Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis 2002; 45: 213-224.
2. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival inprimary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
3. Trulock EP. Lung transplantation for primary pulmonary hypertension. Clin Chest Med 2001; 22: 583-593.
4. Rubin LJ. Executive summary and introduction. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guide. Chest 2004; 126 (Suppl): 4S-10S.
5. Lee AJ, Chiao TB, Tsang MP. Sildenafil for pulmonary hypertension. Ann Pharmacother 2005; 39: 869-884.
6. Karatza AA, Bush A, Magee AG. Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005; 100: 267-273.
7. Maloney JP. Advances in the treatment of secondary pulmonary hypertension. Curr Opin Pulm Med 2003; 9: 139-143.
8. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Ent Respir J 2004; 24: 1007-1010.
9. McLaughin VV, Hoeper MM. Pulmonary arterial hypertension: The race for the most effective treatment. Am J Respir Crit Care Med 2005; 171: 1199-1201.
10. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-1222.
11. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-2403.
12. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-2069.
13. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4.
14. Oliver J, Webb DJ. Sildenafil for "blue babies". Such unlicensed drug use might be justified as last resort. BMJ 2002: 325: 1174.
15. Juliana AE, Abbad FC. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: Successful treatment with sildenafil. Eur J Pediatr 2005; 164: 626-629.
16. Galie N, Ghoftani HA, Torbicki A, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
17. Zolessi R. Pharmacology Perspectives. Epoprostenol (Flolan). J Pharmacy Society Wisconsin 2001; Nov-Dec: 25-29.
18. Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: A preliminary decision analysis. Chest 2003; 124: 2087-2092.
19. Baker SE, Hockman RH. Inhaled iloprost in pulmonary arterial hypertension. Ann Pharmacother 2005; 39: 1265-1274.
20. The pulmonary hypertension Association website. Link: http://www.phassociation.org/Learn/treatments. Accessed October 10, 2005.
21. Petros AJ, Turner SC, Nunn AJ. Cost implications of using inhaled nitric oxide compared with epoprostenot for pulmonary hypertension. J Pharm Technol 1995; 11: 163-166.
22. Angus DC, Clermont G, Watson RS, Linde-Zwirble WT, Clark RH, Roberts MS. Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics 2003; 112: 1351-1360.
23. Pierce CM, Peters MJ, Cohen G, Goldman AP, Petros AJ. Cost of nitric oxide is exorbitant. BMJ 2002; 325: 336.
24. Glantz S. Primer of Biostatistics, 5th edn. McGraw-Hill, United States, 2002.
25. Trachte AL, Lobato EB, Urdaneta F, et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005; 79: 194-197.
26. Kataoka M, Satoh T, Manabe T, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 2005; 69: 461-465.
27. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: Combined administration with inhaled nitric oxide. Chest 2005; 127: 1647-1653.
28. Agapito AF, Sousa L, Oliveira JA, Feliciano J, Cacela D, Quininha J. Eisenmenger syndrome in the adult - experience with new drugs for the treatment of pulmonary hypertension. Rev Port Cardiol 2005; 24: 421-431.
29. Chockalingam A, Gnanavelu G, Venkatesan S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 2005; 99: 91-95.
30. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274-3280.
31. Steiner MK, Preston IR, Klinger JR, Hill NS. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol 2005; 5: 245-250.
32. Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: Acute and mid-term effects. Eur Heart J 2004; 25: 431-436.